US FDA Wants Tavneos Pulled From Market, Amgen Declines

 
• By Mandy Jackson
  
The FDA cited hepatotoxicity concerns with Tavneos and asked that it be withdrawn. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Safety

More from United States